| Name | Title | Contact Details |
|---|---|---|
Scott Hinkelman |
Director of Finance | Profile |
CTI was founded on the belief that a coalition between unique scientific technology and its strong desire to “do right” by the patient could help us achieve our mission to acquire, develop and bring to market less toxic, more effective therapies to treat and cure cancer. We strive to do business better than other biopharmaceutical companies. Better means a more collaborative, well-trained team environment willing to institute novel approaches to scientific discovery and business opportunities. A willingness to push the limits to achieve challenging goals is the essential attribute that sets CTI employees apart.
Insmed is a global biopharmaceutical company focused on the needs of patients with rare diseases. Headquartered in Bridgewater, NJ, Insmed is a dynamic and rapidly growing company with a strong pipeline of drug candidates. At Insmed, we are on a mission to transform the lives of patients battling serious rare diseases. We are developing novel, targeted therapies to help serve the critical unmet needs of these patients. In concert with developing therapeutic solutions, we are committed to improving the entire patient experience. “Insmed is a team of talented and motivated professionals who are dedicated to making a difference in the lives of patients with rare diseases, said Will Lewis, president and CEO at Insmed.
Verdezyne is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Avantra Biosciences FKA Decision Biomarkers, Inc. is a Woburn, MA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Precision NanoSystems Inc. (PNI) creates innovative solutions that empower researchers to harness powerful nanotechnology to transform our understanding and treatment of diseases.